Who makes Flavoquine®, Camoquin® Suspension?

Flavoquine®, Camoquin® Suspension is developed by Pfizer.

What development phase is Flavoquine®, Camoquin® Suspension in?

Flavoquine®, Camoquin® Suspension is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Flavoquine®, Camoquin® Suspension

Pfizer · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Flavoquine®, Camoquin® Suspension
Also known as	amodiaquine
Sponsor	Pfizer
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Flavoquine®, Camoquin® Suspension CI brief — competitive landscape report
Flavoquine®, Camoquin® Suspension updates RSS · CI watch RSS
Pfizer portfolio CI